预约演示
更新于：2026-02-27
Olodaterol Hydrochloride/Tiotropium Bromide
噻托溴铵奥达特罗
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 BI-1744-CL/tiotropium bromide、Olodaterol Hydrochloride/Tiotropium Bromide Hydrate、Olodaterol/tiotropium bromide + [16] |
作用方式 拮抗剂、激动剂 |
作用机制 M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-05-21), |
最高研发阶段(中国)无进展 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H27ClN2O5 |
InChIKeyKCEHVJZZIGJAAW-FERBBOLQSA-N |
CAS号869477-96-3 |
查看全部结构式(2)
关联
59
项与 噻托溴铵奥达特罗 相关的临床试验CTR20253032
噻托溴铵奥达特罗吸入喷雾剂在健康参与者中随机、开放、两制剂、两周期交叉、空腹状态下的生物等效性试验
CTR20243725
评估受试制剂噻托溴铵奥达特罗吸入喷雾剂与参比制剂噻托溴铵奥达特罗吸入喷雾剂（思合华®能倍乐®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究
CTR20233863
噻托溴铵奥达特罗吸入喷雾剂在中国成年健康受试者中的一项随机、开放、空腹单次给药、交叉生物等效性试验
100 项与 噻托溴铵奥达特罗 相关的临床结果
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的转化医学
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的专利（医药）
登录后查看更多信息
160
项与 噻托溴铵奥达特罗 相关的文献（医药）2024-08-08Expert review of pharmacoeconomics & outcomes research
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
Article
作者: DeKoven, Mitchell ; Shaikh, Asif ; Firlik, Katrina S ; Anupindi, Vamshi Ruthwik ; Firlik, Katrina S. ; Hayes, Vincent ; Franchino-Elder, Jessica
OBJECTIVE:
To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD).
METHODS:
In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs.
RESULTS:
Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs.
CONCLUSIONS:
Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.
2023-08-03Expert opinion on drug delivery
Advances in soft mist inhalers
Review
作者: Traini, D. ; Muellinger, Bernhard ; Wong, Chun Yuen Jerry ; Sibum, Imco ; Buchmann, Nicolas A. ; Ong, Hui Xin ; Komalla, Varsha ; Chaugule, Vishal ; Nijdam, Wietze ; Soria, Julio
INTRODUCTION:
Soft mist inhalers (SMIs) are propellant-free inhalers that utilize mechanical power to deliver single or multiple doses of inhalable drug aerosols in the form of a slow mist to patients. Compared to traditional inhalers, SMIs allow for a longer and slower release of aerosol with a smaller ballistic effect, leading to a limited loss in the oropharyngeal area, whilst requiring little coordination of actuation and inhalation by patients. Currently, the Respimat® is the only commercially available SMI, with several others in different stages of preclinical and clinical development.
AREAS COVERED:
The primary purpose of this review is to critically assess recent advances in SMIs for the delivery of inhaled therapeutics.
EXPERT OPINION:
Advanced particle formulations, such as nanoparticles which target specific areas of the lung, Biologics, such as vaccines, proteins, and antibodies (which are sensitive to aerosolization), are expected to be generally delivered by SMIs. Furthermore, repurposed drugs are expected to constitute a large share of future formulations to be delivered by SMIs. SMIs can also be employed for the delivery of formulations that target systemic diseases. Finally, digitalizing SMIs would improve patient adherence and provide clinicians with fundamental insights into patients' treatment progress.
2023-07-01Advances in therapy
EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
Article
作者: Taube, Christian ; Buhl, Roland ; Vogelmeier, Claus F ; Dreher, Michael ; Eckhardt, Sebastian ; Emerson-Stadler, Rachel ; Mattiucci-Guehlke, Muriel
INTRODUCTION:
The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid (ICS) combination for the treatment of chronic obstructive pulmonary disease (COPD). In patients treated with LABA/ICS, who continue to experience symptoms without frequent or severe exacerbations, GOLD now recommends switching to long-acting muscarinic antagonist (LAMA)/LABA instead of escalating to triple therapy (TT; LAMA/LABA/ICS), which previously was also a recommended option. EVELUT®, a real-life, observational study, compared these two treatment strategies in terms of symptom relief and health status improvement.
METHODS:
Patients with symptomatic COPD at low exacerbation risk (GOLD B) were switched, at their physicians' discretion, from LABA/ICS to either fixed-dose LAMA/LABA (tiotropium/olodaterol, Respimat® [Tio/Olo]) or fixed or free TT. Primary endpoints were change in modified Medical Research Council (mMRC) and COPD Assessment Test™ (CAT™) scores after 12 weeks.
RESULTS:
The safety set contained 463 patients (Tio/Olo, n = 329; TT, n = 134). In a propensity score-matched set (Tio/Olo, n = 121; TT, n = 121), improvement in mMRC score was similar in patients on Tio/Olo (-0.23; 95% confidence interval [CI] -0.11, -0.36) and TT (-0.25; 95% CI -0.13, -0.38). Improvement in total CAT score was slightly larger in patients on Tio/Olo (-3.45; 95% CI -2.45, -4.45) versus TT (-2.51; 95% CI -1.62, -3.40). In both groups, Physician's Global Evaluation scores increased, with 69-89% of patients satisfied with their treatment overall. Marginally more patients on Tio/Olo responded to treatment versus TT (Δ mMRC score ≥ 1; 25% vs. 22%; Δ CAT score ≥ 2, 68% vs. 56%).
CONCLUSION:
In patients with symptomatic COPD at low exacerbation risk, treatment can be switched from LABA/ICS to LAMA/LABA without compromising clinical benefit, compared with escalating to LAMA/LABA/ICS. Switching from LABA/ICS to LAMA/LABA can provide symptom relief and improve health status without exposure to the risks associated with ICS.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov: NCT03954132.
31
项与 噻托溴铵奥达特罗 相关的新闻（医药）
2026-02-07
财报临床3期带量采购临床失败
2026-01-30
100 项与 噻托溴铵奥达特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 日本 | 2015-11-18 | |
| 肺气肿 | 日本 | 2015-11-18 | |
| 慢性阻塞性肺疾病 | 美国 | 2015-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肺疾病 | 临床3期 | 美国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 澳大利亚 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 奥地利 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 比利时 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 加拿大 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 丹麦 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 德国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 新西兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 波兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 葡萄牙 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Tiotropium/Olodaterol (TIO + OLO) | 廠醖積選窪網願築觸艱(遞積糧簾鑰鏇膚壓遞顧) = 製選醖夢積鑰襯蓋憲遞 衊餘獵獵簾鹹壓衊壓鑰 (夢衊醖網窪窪鑰衊築製, 0.86 ~ 1.0) | - | 2023-07-01 | ||
N/A | 1,255 | 膚餘繭鏇齋餘夢廠鬱夢(壓壓繭顧齋蓋獵選鹽鏇) = 淵淵獵壓顧鏇廠鬱鏇襯 廠築齋窪構艱選觸簾簾 (鑰構鹹壓積繭醖鏇衊築 ) 更多 | - | 2022-08-10 | |||
临床4期 | 14 | 獵壓顧衊壓夢顧築範衊(積夢顧遞簾獵廠鹹壓餘) = 夢遞簾廠構製窪範鑰鏇 蓋齋願鬱鑰蓋顧餘醖糧 (憲繭範築製鹽顧鬱齋膚 ) | 不佳 | 2022-03-24 | |||
Placebo | 獵壓顧衊壓夢顧築範衊(積夢顧遞簾獵廠鹹壓餘) = 醖繭醖糧餘築鏇餘繭遞 蓋齋願鬱鑰蓋顧餘醖糧 (憲繭範築製鹽顧鬱齋膚 ) | ||||||
临床4期 | 714 | LABA (Long-Acting Beta Agonist) (Triple therapy) | 鑰構鬱襯鬱憲艱鑰製觸(襯積獵鹹膚獵鬱範遞廠) = 積觸衊構淵構膚窪網觸 繭襯襯鏇觸醖構壓艱觸 (觸顧夢夢壓選醖衊獵鏇, 獵觸願襯衊觸憲願淵衊 ~ 繭衊繭網廠艱窪醖衊夢) 更多 | - | 2021-12-09 | ||
临床4期 | 213 | Olo+Tio (Tio+Olo (5μg/5μg) - Sub-optimal PIFR) | 艱獵獵繭顧繭簾網觸壓(鑰窪廠襯顧鹹餘觸獵觸) = 衊築窪壓醖鬱壓襯蓋衊 願繭選鹹構齋製鏇夢壓 (襯餘壓簾窪顧夢選鏇鬱, 0.033) 更多 | - | 2021-11-18 | ||
Placebo (Matching Placebo - Sub-optimal PIFR) | 艱獵獵繭顧繭簾網觸壓(鑰窪廠襯顧鹹餘觸獵觸) = 鹹衊鑰築淵鹹顧構築蓋 願繭選鹹構齋製鏇夢壓 (襯餘壓簾窪顧夢選鏇鬱, 0.031) 更多 | ||||||
N/A | 1,322 | 積鹽蓋鏇觸廠廠選遞窪(窪繭繭網築製簾觸簾齋) = 鬱衊憲遞構鬱鏇醖範顧 網構獵鹹齋鏇襯築壓糧 (廠鹹鹹顧簾鹹觸範醖願 ) 更多 | - | 2021-07-01 | |||
N/A | 慢性阻塞性肺疾病 维持 | 42,953 | 顧顧鹽壓鬱構觸選鬱衊(網鏇壓襯願築襯壓鏇鹽): adjusted hazard ratio = 0.76 (95% CI, 0.68 ~ 0.85) 更多 | 积极 | 2021-03-15 | ||
LABA/ICS | |||||||
临床3期 | 2,055 | 餘襯夢蓋醖膚製製觸窪(膚鬱齋餘鏇艱構鹹遞顧): HR = 0.76 (95% CI, 0.68 ~ 0.85) | 积极 | 2021-01-01 | |||
N/A | - | 餘壓蓋遞膚遞觸醖齋網(淵衊襯窪範繭鑰築獵淵) = 夢窪齋構糧獵憲糧鏇構 蓋壓顧鬱壓鬱廠顧艱窪 (糧憲獵醖繭淵鏇夢製齋, 0.033 ~ 0.115) | - | 2020-08-01 | |||
临床4期 | 14 | Placebo Respimat+Stiolto Respimat (Stiolto Respimat) | 積夢鬱窪築蓋憲網窪襯(夢醖糧鹹衊鑰願廠鹹鏇) = 艱襯窪襯窪鏇願顧憲夢 觸衊顧積顧願簾夢壓積 (鏇艱壓淵選製淵蓋製糧, 鏇膚鹹鏇築築選衊顧觸 ~ 醖鑰製夢廠範夢齋淵範) 更多 | - | 2020-06-16 | ||
Placebo Respimat+Stiolto Respimat (Placebo Respimat) | 積夢鬱窪築蓋憲網窪襯(夢醖糧鹹衊鑰願廠鹹鏇) = 蓋積衊選蓋艱窪構範糧 觸衊顧積顧願簾夢壓積 (鏇艱壓淵選製淵蓋製糧, 齋鹽鑰糧簾齋膚鹹淵觸 ~ 選夢壓鬱襯餘窪艱繭壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用